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Vijay Kumar Kuna, MSc,a Antonio Rosales, MD,b Jonny Hisdal, PhD,b Eivind K. Osnes, MD, PhD,b
Jon O. Sundhagen, MD,b Henrik Bäckdahl, PhD,c Suchitra Sumitran-Holgersson, PhD,a and
Jørgen J. Jørgensen, MD, PhD,b,d Gothenburg and Borås, Sweden; and Aker and Oslo, NorwayObjective: The purpose of this study was to evaluate whether
tissue-engineered human allogeneic vein valves have a normal
closure time (competency) and tolerate reﬂux pressure in vitro.
Methods: Fifteen human allogeneic femoral vein segments
containing valves were harvested from cadavers. Valve closure
time and resistance to reﬂux pressure (100 mm Hg) were
assessed in an in vitro model to verify competency of the vein
valves. The segments were tissue engineered using the tech-
nology of decellularization (DC) and recellularization (RC).
The decellularized and recellularized vein segments were
characterized biochemically, immunohistochemically, and
biomechanically.
Results: Four of 15 veins with valves were found to be incom-
petent immediately after harvest. In total, 2 of 4 segments with
incompetent valves and 10 of 11 segments with competent
valves were further decellularized using detergents and DNAse.
DC resulted in signiﬁcant decrease in host DNA compared with
controls. DC scaffolds, however, retained major extracellular
matrix proteins and mechanical integrity. RC resulted in suc-
cessful repopulation of the lumen and valves of the scaffold with
endothelial and smooth muscle cells. Valve mechanical param-
eters were similar to the native tissue even after DC. Eight of 10the Laboratory for Transplantation and Regenerative Medicine, Depart-
ent of Surgery, Sahlgrenska Academy at the University of Gothenburg,
othenburga; the Department of Vascular Surgery, Oslo Vascular Centre,
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d Surfaces, SP Technical Research Institute of Sweden, Boråsc; and the
ascular Department, University of Oslo, Oslo.d
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edish Research Council K2013-65X-22347-01-3, and the Inga-Britt
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or conﬂict of interest: S.S.H. is a cofounder and board member of
ovaHep AB, a company that has licensed the technology of tissue engi-
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slo University Hospital are coinventors.veins with competent valves remained competent even after DC
and RC, whereas the two incompetent valves remained incom-
petent even after DC and RC. The valve closure time to reﬂux
pressure of the tissue-engineered veins was <0.5 second.
Conclusions: Tissue-engineered veins with valves provide a valid
template for future preclinical studies and eventual clinical ap-
plications. This technique may enable replacement of diseased
incompetent or damaged deep veins to treat axial reﬂux and thus
reduce ambulatory venous hypertension. (J Vasc Surg: Venous
and Lym Dis 2015;3:421-30.)
Clinical Relevance: The use of natural, human scaffolds to
produce tissue-engineered venous segments containing func-
tioning valves will revolutionize the surgical correction of deep
venous reﬂux in patients with chronic venous insufﬁciency and
leg ulcer. Reconstructive deep venous surgery in the form of
valvuloplasty, transplantation, and neovalve construction has
met limitations in the rare availability of valves to be repaired,
lack of donor sites, and inadequate conditions to create new
valves. This tissue-engineered procedure produces the func-
tioning unit “valve-conduit,” and surgery will be used only to
implant it.Chronic venous insufﬁciency (CVI) describes a condi-
tion that affects the venous system of the lower extremities,
in which persistent ambulatory venous hypertension is the
main pathophysiologic factor leading to pain, edema, skin
changes, and ulcerations.1 The more serious consequences
of CVI, such as venous ulcers, have an estimated prevalence
of 0.1% to 1.0%.2,3 The overall prognosis of venous ulcers is
poor.4 Risk factors found to be associated with CVI include
age, sex, family history of varicose veins, obesity, preg-
nancy, and phlebitis.5,6 The ﬁnancial burden of venous ul-
cer disease on the health care system is an estimated $1billion spent annually on treatment of chronic wounds in
the United States or #2% of the total health care budget
in Western countries.
The conventional treatment of CVI with compression
stockings combined with superﬁcial surgery seems to
improve venous hemodynamics but achieves only a 65% ul-
cer healing rate after 24 weeks, with a recurrence rate of
12%/year.7 Reconstructive deep venous surgery, such as
valvuloplasty, autotransplantation, and neovalve construc-
tion, has proved to be an option, improving ulcer healing
rates and providing an ulcer-free period in patients forAdditional material for this article may be found online at www.jvsvenous.org.
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Fig 1. Picture of the setup and in vitro model for functional testing of veins. A, The system is circulated with room-
temperature saline containing an ultrasound contrast agent for enhancement of the Doppler signals. A peristaltic pump
(a) pumps the saline through the whole circuit; a mechanical valve (b) enables ﬂow through the vein (c) during output
from the pump. An ultrasound probe (d) is used for visualization of the vein (e) and evaluation of the ﬂow through the
vein valve. Reﬂux pressure at the valve site is adjusted by the height of the reservoir (f) above the vein. B, Enlarged
picture of a valve-bearing venous segment mounted in the circuit and placed in a container ﬁlled with saline to facilitate
visualization by ultrasound.
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422 Kuna et al October 2015whom conventional treatment has failed. Axillary or saphe-
nous transplantation to treat axial reﬂux in these patients
has been reported to yield ulcer healing rates of up to
70%. However, the durability of these procedures remains
an issue, taking into consideration that the average age of
patients in reported materials is about 50 years, and only
half of the transplants remained functional after 4 years.8-11
In addition, the demanding surgical technique needed has
limited the use of reconstructive deep venous surgery to
very few centers, and although reports have been produced
that show good results, no randomized clinical trials have
yet been published. Experimental efforts to understand
the venous valve function to be able to create mechanical
and bioprosthetic valves also exist. The challenges encoun-
tered are to avoid immune reaction, thrombogenicity, and
migration in the vein.12-16
Thus, given the prevalence and socioeconomic impact
of CVI and the poor treatment modalities available for it,
alternative, more effective therapeutic options need to be
explored. Regenerative medicine may offer novel strategies
to treat these patients. Tissue-engineered venous segments
containing competent valves might represent a more dura-
ble solution for this young group of patients. In addition,
the required surgical skills will not be as demanding (inter-
position of a vein segment), which might help spread this
possibility of treating severe CVI cases.
Perfusion decellularization (DC) and recellularization
(RC) of tissues and organs is believed to be a successful
platform technology for creating scaffolding materials for
tissue engineering and regenerative medicine.17,18 DC is
the process of removal of all host cells and nuclear material
by physical, chemical, and enzymatic methods.19 Thus,
whole organ acellular matrices provide an attractive scaffoldfor the repopulation with cells for an engineered tissue or
organ because of the physiologic resemblance to the original
tissue, including intact three-dimensional anatomic architec-
ture, preserved spatial array of extracellular matrix (ECM)
components, vascular network, and biomechanical proper-
ties. Creating regenerated donor organs by repopulating
organ scaffolds with patient-speciﬁc mature or stem
cell-derived populations would allow us to personalize trans-
plantation medicine and reduce the need for long-term
immunosuppressive therapy. Using this approach, we
recently tissue engineered human veins using autologous
stem cells from the patients and successfully transplanted
three pediatric patients with portal vein thrombosis.20,21 In
the present study, we have further expanded the application
of this technology to tissue engineer human veins containing
valves.Wehypothesized that vein segmentswith valves tissue
engineered by the technology of DC and RCwith stem cells
would yield a blood vessel with physiologic properties resem-
bling the original tissue and that the valves would retain their
competency, making them resistant to reﬂux.
METHODS
The Swedish and Norwegian Institutional Review Boards
and Ethics Committees approved all research protocols.
Harvesting of valve-bearing veins. All veins (N ¼
15) used in this study were harvested at Oslo University
Hospital, Norway. Vein segments about 8 cm (range,
5.5-10 cm), including the common femoral vein, profunda
femoral vein, and femoral vein, were harvested from adult
human cadavers by using vascular surgical technique and
carefully ligating all side branches. Valves were identiﬁed,
and 15 segments were cut with a margin of 3 to 4 cm on
each end of the valves. Sterile saline solution was injected
Fig 2. Gross morphology and microscopic view of the decellularized valve-containing vein segments. Gross
morphology of (A) native vein and (B) decellularized vein after 14 cycles. Hematoxylin and eosin (HE) staining of (C)
decellularized vein after 14 cycles showing preserved tissue architecture and absence of blue-black nuclei and (D) a
native vein (positive control) showing presence of nuclei. DAPI staining of native vein showed several nuclei (E), but
not in (F) decellularized vein. Immunohistochemical staining of decellularized veins showed absence of HLA class I
(G) and class II (H) antigen expression. Normal vein (positive control) stained positive for HLA class I (I, brown) but
not HLA class II (J). K, Negative control.
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retainment of solution above the valves. It was also possible
to see the valve leaﬂets closing. We had approximately 8-
cm segments of the veins with a valve in the middle.
Four of 15 veins with valves were found to be incompetent
immediately after harvest. All vein segments were thor-
oughly rinsed in phosphate-buffered saline (PBS) contain-
ing 0.5% penicillin, 0.5% streptomycin, and 0.5%
amphotericin B and preserved at 4C. The samples were
transported within 1 week on ice to the Laboratory for
Transplantation and Regenerative Medicine at the
Sahlgrenska University Hospital, Gothenburg, Sweden. In
total, 2 incompetent veins and 1 competent vein with
valves were used for the biomechanical tests, whereas 10
competent and 2 incompetent veins with valves were used
for DC and RC.
Functional in vitro testing of valve-bearing veins.
This test was performed at the Oslo Vascular Centre, Oslo
University Hospital, Norway. A custom-made test setup
was used to assess the functionality of the veins before and
after RC (Fig 1, A). The in vitro test setup used in the
present study for evaluating the functionality is a modiﬁca-
tion of the one used by Geselschap et al.22 The aim of our
setup was basically to have a model that would allow us to
assess venous valve function only at a determined pressure.The vein was mounted vertically in the in vitro ﬂow cir-
cuit and perfused with room-temperature saline. The vein
was connected to the ﬂuid circuit by conic connectors,
secured with sutures at both ends (Fig 1, B). A commercial
peristaltic pump (Model No. 700044; Baxter Healthcare
Corp, Deerﬁeld, Ill) delivered intermittent ﬂow to the
circuit.
A mechanical valve was used to regulate the ﬂow direc-
tion through the circuit during outﬂow from the pump,
and when the same valve was switched to open position,
it achieved backﬂow in the vein until the valve closed.
Reﬂux pressure in the vein was adjusted by the height of
the column of ﬂuid above the valve. The choice of reverse
ﬂow pressure level at 100 mm Hg was based on the esti-
mated distance between the heart and the popliteal fossa
and supported by the mathematical model published by
Fragomeni et al.23 Ultrasound Doppler technique was
used to detect potential reﬂux at the site of the venous
valve (9 MHz linear probe, Vivid E9; GE Healthcare, Bos-
ton, Mass). To optimize the visualization with ultrasound,
the vein segment was submerged in a plastic container ﬁlled
with saline. A contrast agent (SonoVue; Bracco Diagnos-
tics, Cranbury, NJ) was administered in the saline solution
to enhance the echogenicity and to enable recordings of
the ﬂow and ﬂow direction in the circuit through the
Fig 3. Extracellular matrix (ECM) in decellularized veins. A,Masson trichrome (MT) staining of normal vein (positive
control) showing presence of nuclei (black), cytoplasm (red/pink), and collagen (blue). B, In the decellularized vein, no
nuclei were found, indicating lack of endothelial and smooth muscle cells, but with abundant collagen still present. C,
Graphs showing decrease in amount of collagen (n ¼ 5), signiﬁcant increase in elastin (n ¼ 5; P ¼ .03), and signiﬁcant
decrease in glycosaminoglycans (GAGs; n ¼ 5; P ¼ .007), respectively, after 14 decellularization (DC) cycles in
comparison to native (N).D, Graph showing signiﬁcant decrease in amount of DNA after DC (P ¼ .0002). Scale bar A
and B, upper panel ¼ 50 mm, and lower panel ¼ 25 mm.
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ﬂow was used as a measure of valve closure time. In addi-
tion, the vein diameter was measured at the site of the
leaﬂet at a reﬂux pressure at 100 mm Hg.
DC and characterization of veins. The processes of
DC, RC, and associated analysis were carried out in Goth-
enburg, Sweden. DC was carried out as described by us
earlier using 1% Triton, 1% tri-n-butyl phosphate (TnBP),
and 4 mg/L DNAse.20 In brief, the veins were washed
for 72 hours in distilled water. One end of the vein was
sealed with 4-0 suture, and the vein was ﬁlled with the
decellularizing solution; the other end was clamped. The
vein was placed in a container with the same solution and
agitated on a shaker for 4 hours at 170 rpm and 37C. All
the solutions used for DC contained 0.02% sodium azide
(71290; Sigma-Aldrich, Seelze, Germany) and 0.18%
EDTA (ED2SS; Sigma-Aldrich). Triton (X-100; Sigma-
Aldrich) and TnBP (A16084; Alfa Aesar, Karlsruhe,
Germany) solutions were prepared in distilled water;
DNase was prepared in PBS containing calcium and mag-
nesium (D8662; Sigma-Aldrich). After every detergent, the
veins were washed with distilled water for 10 minutes. The
procedure from Triton to DNase is termed one cycle. The
decellularized vein segments were evaluated for residual
DNA content, staining with hematoxylin and eosin (HE)
and Masson trichrome (MT) by standard procedures for
acellularity and quantiﬁcation of various ECM proteins.
Immunohistochemistry for detection of HLA class I and
class II antigens was performed by standard procedure.
See the Supplementary Methods (online only) for
details of DNA quantiﬁcation, ECM staining andquantiﬁcation, acid- and pepsin-soluble collagen quantiﬁ-
cation, sulfated glycosaminoglycan (GAG) quantiﬁcation,
and soluble elastin quantiﬁcation.
RC of veins. On the day of RC, 20 to 25 mL of pe-
ripheral venous blood was collected from healthy donors
(age group, 25-35 years) in sterile heparin-coated Vacu-
tainer tubes and transported to the laboratory as soon as
possible (within 2 hours). Healthy donors were individuals
and personnel with no obvious diseases or disorders and
with no venous reﬂux disease. The volume of blood
required was determined by the length of the vessel and of
the pipes used in the bioreactor.
The entire RC process was performed under sterile condi-
tions, and all perfusions were carried out in an incubator at
37C supplied with 5% CO2. Before RC, the veins were
perfused with heparin (387107; LEO Pharma, Malmö, Swe-
den) at a concentration of 50 IU/mL PBS for 2 hours. The
heparin was drained off, and whole blood was immediately
perfused for 48 hours at 2 mL/min speed. The blood was
then drained off, and the vein was rinsed with PBS containing
1% penicillin-streptomycin-amphotericin until blood was
completely removed. The vein was subsequently perfused
4 days with endothelial and 4 days with smoothmusclemedia.
The complete endothelial medium was prepared with
MCDB131 (10372; Life Technologies, Stockholm, Sweden)
basalmediumsupplementedwith10%heat-inactivatedhuman
AB serum (34005100; Life Technologies), 1% glutamine
(25030; Lonza, Copenhagen, Denmark), 1% penicillin-
streptomycin-amphotericin, and EGM-2 SingleQuot kit
(CC4176; Lonza) that contained ascorbic acid, hydrocorti-
sone, transferrin, insulin, recombinant human vascular
Fig 4. Characterization of recellularized valve containing vein segments. A, Gross picture of a recellularized vein
showing valves. B and C,Hematoxylin and eosin (HE)-stained microscopic pictures of a recellularized vein and valve at
low and high magniﬁcation, respectively. The pictures show presence of continuous cells at endothelial lining on both
vein and valve (arrow). D, HE and Masson trichrome (MT) staining of normal (positive control) and recellularized
valves showing presence of nuclei in all. E, CD31 staining of a recellularized vein showing continuous endothelial
lining. F, Alpha smooth muscle actin staining of valve showing presence of smooth muscle cells in the valve. G, Alpha
smooth muscle actin staining showing smooth muscle cells in media of a recellularized vein.
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factor, human epithelial growth factor, heparin, and genta-
micin sulfate. The complete smooth muscle medium was pre-
pared using 500mLMedium231 (M231; Life Technologies)
supplied with 10% heat-inactivated human AB serum, 1%
penicillin-streptomycin-amphotericin, and 20 mL of smooth
muscle growth supplement (S00725; Life Technologies).
Vein scaffolds were recellularized for a total of 10 days.21
See the Supplementary Methods (online only) for de-
tails of characterization of recellularized veins, biomechan-
ical analysis, sterility control test, and statistics.
RESULTS
Functional in vitro testing of cadaveric valve-
bearing veins. A total of 15 femoral vein specimens
were harvested from human cadavers. The median time be-
tween death and harvest was 3 days (2-6) and between
death and testing, 6 days (5-7). Four of 15 veins with
valves were incompetent immediately after harvest. In gen-
eral, the median diameter of the vein specimens was
9.8 mm (7.5-14) and 9.8 mm (8-14.2) after RC. The 11
vein segments with competent valves (normal closure
time #0.5 second at a pressure of 100 mm Hg)24 andthe 4 vein segments with incompetent valves were then
transported to Sweden. In Sweden, further examination of
the four incompetent valves showed presence of holes in
the valves of two veins, mechanical damage in one, and no
apparent problems with the fourth. This was examined by
turning the veins inside-out. Two of the four incompetent
veins with valves were used for biomechanical testing; the
other two were used for DC and RC. Further, one vein
with competent valves was used for biomechanical testing,
whereas 10 of 11 were used for DC and RC. Thus, in total,
3 of 15 veins were used for biomechanical studies, whereas
12 of 15 were used for DC and RC.
We found that 8 of 10 segments with competent valves
retained their competency after the RC process, whereas 2
showed reﬂux already after DC. In both cases, the valves in
the segments were damaged mechanically while the speci-
mens were handled during DC. In addition, the two seg-
ments with incompetent valves already at the start were
also found to be incompetent even after DC and RC.
Thus, RC did not repair the damaged valves.
DC, characterization, and functional in vitro
testing of decellularized valve-bearing veins. Treatment
with 1% Triton and 1% TnBP successfully decellularized the
Fig 5. Macroscopic and microscopic views of the bioengineered vein grafts with autologous whole peripheral blood. A,
Gross morphology of recellularized vein appearing pinkish in color. B and C, Immunoﬂuorescence staining of tissue-
engineered vein (B) and valve (C) showing presence of endothelial cells (green) in the lumen when stained with an-
tibodies to von Willebrand factor. D, Negative control. E, DAPI staining showing abundant nuclei in normal vein and
vein recellularized with peripheral whole blood. F, The picture shows functioning valves when a solution is ﬂushed
through native, decellularized (DC), and recellularized (RC) veins. B-D,Magniﬁcation 400. E,Magniﬁcation 100.
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vein (Fig 2, A) and a decellularized vein (Fig 2, B)
appeared pale and translucent. There was absence of nuclei
in the veins (Fig 2, C) of all specimens tested after 14 cycles
as detected by HE staining compared with native (Fig 2, D).
This was further conﬁrmed by DAPI staining in native and
DC veins (Fig 2, E and F). In addition, no positive staining
for HLA class I (Fig 2, G) or class II antigens (Fig 2,H) was
detected compared with native veins (Fig 2, I and J). Note
that normal endothelial cells and smooth muscle cells do
not constitutively express HLA class II (Fig 2, J). Fig 2, K
shows no staining in the negative control. MT staining
showed the presence of an abundant amount of collagen
(blue color) but no nuclei (black) after DC (Fig 3, A and B).
The quantiﬁcation of collagen, elastin, and GAGs with
Sircol, Fastin, and Blyscan assays (Biocolor, County Antrim,
United Kingdom), respectively (Fig 3, C), showed signiﬁ-
cant loss of GAGs (P ¼ .007) and signiﬁcant increase in
elastin (P ¼ .03) but not collagen (P ¼ .09) compared with
native veins. The DC protocol also led to signiﬁcant
decrease in DNA amount from 241.95 6 39.44 ng/mg of
tissue in normal veins to 22.44 6 6.29 ng/mg in decellu-
larized veins (Fig 3, D) (P ¼ .0002). All decellularized veins
were tested for functionality by ﬂushing a ﬂuid retrograde
through the valves. Two of 10 competent valves showed
reﬂux, demonstrating loss of their function during DC; 8valves did not show reﬂux, indicating no effect of DC on
function. Four decellularized veins were tested for valve
closure time using in vitro setup, and the valve closure time
was <0.5 second.
RC, characterization, and functional in vitro testing
of recellularized valve-bearing veins. All 12 decellular-
ized veins were recellularized in a custom-designed
bioreactor with peripheral blood. Fig 4, A shows the
gross morphology of recellularized veins containing
valves. HE staining showed the presence of several nuclei
(blue) in the vein (Fig 4, B) and the valves (Fig 4, C). HE
and MT staining of recellularized vein valves also showed
abundant nuclei (blue and black, respectively; Fig 4, D).
In addition, immunohistochemistry staining with endo-
thelial cell marker CD31 showed a continuous endothe-
lial cell layer in veins (Fig 4, E); staining with smooth
muscle actin conﬁrmed the presence of spindle-shaped
smooth muscle cells in the valves (Fig 4, F) and tunica
adventitia of the veins (Fig 4, G). The gross morphology
of recellularized veins appeared pinkish with good tunica
externa (Fig 5, A). Immunoﬂuorescence staining with
antibodies to another endothelial cell marker, von
Willebrand factor (green), conﬁrmed the presence of
endothelial cells in the lumen (Fig 5, B) and the valves
(Fig 5, C) compared with the negative control (Fig 5, D).
Fig 5, E depicts the DAPI staining of a native and
Fig 6. Functional testing of tissue-engineered valve-containing veins. A, Two-dimensional pictures from ultrasound
show a longitudinal projection of the vein segment: a closed valve (a); the gradual opening of the valve during
antegrade ﬂow (b-d); and the closing of the valve with retrograde ﬂow (e and f). B, The yellow Doppler scale gives the
valve closure time in seconds.
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both sections. Testing of valve function showed that
freshly harvested, decellularized and recellularized veins
distend when ﬂushed with ﬂuid through a syringe (Fig 5,
F). Ultrasound testing demonstrated the gradual opening
of the valve during antegrade ﬂow and closing of the valve
with retrograde ﬂow (Fig 6, A), and the Doppler scale
revealed the valve closure time in seconds (Fig 6, B;
Video, online only). Only 8 of 12 recellularized veins
were functional. The veins that lost function while
decellularized and the veins nonfunctional from the
beginning did not show function.
Biomechanical testing of the valves. In total, six
recellularized veins (n ¼ 12 valves) and three normal
veins (n ¼ 6 valves) were tested. The vein valves were
gradually torn apart starting from the suture. The tear
progressed horizontally, giving rise to peaks when the ﬁ-
bers of the valve broke. Eventually one of the ends of the
valve was torn from the vein wall, as indicated by the last
peak in the force/elongation diagram (Fig 7, A). Forces
at ﬁrst break (peak) were above 0.8 N for all vein valves
that proved to function in the functional in vitro test
(Fig 7, B). The median force was not signiﬁcantly
different between normal and RC functional valves
(Fig 7, C).Sterility control test. In both culture media of all the
veins, no marked increase in absorbance was recorded at
14 days of culture. The optical density at 600 nm measured
in the spectrophotometer for fresh media (0.006) was
similar to that of perfused media (0.010), which was the
same as the negative control (0.010). The optical density
of the positive control was high (0.135). No colonies of
bacteria or fungal growth were seen on the tryptone soya
agar plates, conﬁrming sterility of the vein segments.
DISCUSSION
For the ﬁrst time, we demonstrate the successful pres-
ervation of valve function of tissue-engineered human
valve-bearing vein segments in an in vitro setting. The
main aim of the study was to demonstrate that the technol-
ogy of DC and RC generates a graft with a competent
valve, provided the native vein already has a functioning
valve. The present study also demonstrates the successful
re-endothelialization of decellularized human vein seg-
ments and vein valves with a simple peripheral blood sam-
ple that enabled signiﬁcantly the formation of extracellular
monolayers. Although transplant donors would provide
fresher tissue, we for the ﬁrst time explored the use of ca-
davers as a source of the tissue. Interestingly, the majority
of the vein segments taken from human cadavers 4 to
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used for tissue engineering. This promising observation can
help increase the pool of blood vessel donors. Because of
the lack of transplant donors and limited access to these
types of donors, we are currently developing a program
for using cadaver veins. The ability of the decellularizing
process to leave “footprints” for RC may open the possibil-
ity for brain-dead, heart-beating transplant donors and
xenograft tissue.
We found it important for the specimen to be har-
vested with precise vascular surgical technique, and the dis-
tance between the actual vein valve and the ends should be
at least 4 cm. In a future clinical study, we intend to test the
specimens after each of the following procedures: (1) har-
vesting, (2) DC, and (3) RC. We believe that the in vitro
model can be further simpliﬁed by connecting the vein
segment directly to a ﬂuid reservoir that is placed at
1.36 meters (100 mm Hg) high to assess the competence
of the veins.
Mechanical analysis of the valves showed that in most
of the functioning valves, the force at ﬁrst peak was above
0.8 N for both vein valves in a pair, indicating that 0.8 N
may be the cutoff criterion required to deﬁne strength of
functional valves. However, larger numbers of samples
will have to be tested to conﬁrm this interesting ﬁnding,
and such studies are ongoing in our laboratory.
Interestingly and importantly, the vein specimen’s
structure and function do not seem to be affected by a win-
dow of time of up to 7 days from death to harvest andtesting. Thus, the pool of cadaver donors for blood vessels
can be increased enormously. The histologic results
showed that DC with Triton/TnBP/DNase was complete,
as adjudged by DNA quantiﬁcation, which was <50 ng/
mg weight. It is reported that >50 ng/mg dry weight is
normally required to evoke a potential immunologic
activity.25
We found that perfusion of peripheral whole blood re-
sults in the formation of a clear extracellular monolayer and
presence of smooth muscle cells in the media. The use of a
simple peripheral blood sample to recellularize the vein seg-
ments is a clear advantage over the more tedious approaches,
such as isolation and expansion of mature cells or stem cells
frombonemarrowor peripheral blood. In our recent study,21
we reported that the major cell types in circulating peripheral
blood that contribute to re-endothelialization and smooth
muscle cell repopulation are VEGFR2þ/CD45þ cells and a
small fraction of VEGFR2þ/CD14þ cells. Furthermore,
function and strength were also preserved in the recellular-
ized vein valves as indicated by results obtained using the
in vitro test model and biomechanical test. Thus, the present
results are further supported by our recently published clinical
proof-of-concept study, in which we successfully transplanted
three pediatric patients with tissue-engineered veins using
autologous peripheral whole blood. Interestingly, none of
the four incompetent veins with valves regained their compe-
tency after RC, indicating that cells and elastin on the valves
are not critical factors for valve functionality. However, a
greater number of incompetent valves need to be tissue
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cording to our observations, maintenance of the mechanical
property may be one of the most important factors for
competency.
Patients with CVI who prove refractory to conven-
tional treatment may beneﬁt from reconstructive deep
valve reconstruction. However, this is a treatment that is
not widespread and readily available because of complex
workup and demanding surgical technique. Both venous
valve transfer and valve construction have a durability
that could be improved because the average age of these
patients is 50years.8-11 Venous valvuloplasty has been re-
ported to provide competency in z60% and ulcer-free
recurrence in z60% at 30 months.26 Other procedures
for reconstruction of nonfunctioning venous valves result-
ing from post-thrombotic valve destruction include
transposition, transplantation, cryopreserved vein valve al-
lografts, and neovalve construction. Cryopreserved vein
valve allografts have also been used but are limited
because of frequent complications, such as early throm-
bosis and poor patency and competency.27 Thus, recon-
structive deep venous surgery in the form of
valvuloplasty, transplantation, and neovalve construction
has its limitations. However, the use of natural, human
scaffolds to produce tissue-engineered venous segments
containing functioning valves may revolutionize the surgi-
cal correction of deep venous reﬂux in patients with CVI
and leg ulcer.
Although the results are promising, this is an in vitro
study and cannot predict the outcome for future human
implantations. Other limitations are the small number of
patients studied and the limited number of biomechanical
studies performed on decellularized valves. It would also
be good in future studies to include tests such as burst pres-
sure and compliance. Tissue-engineered valve-containing
vein segments may be a therapeutic option in selected pa-
tients in whom deep venous reﬂux and venous hyperten-
sion are the main pathophysiologic features leading to
recurrent leg ulcer. We believe that the results of the pre-
sent study are encouraging and constitute the basis
required to start a clinical pilot study.
CONCLUSIONS
In the future, personalized tissue-engineered veins with
competent valves may enable the replacement of incompe-
tent or destroyed deep vein valves in patients with CVI.
We wish to thank Pradeep B. Patil for design of the
bioreactor used in the study.
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DNA quantiﬁcation. DNA was extracted from seven
native and nine decellularized veins by use of a commer-
cially available kit; 20 mg of tissue was collected, and
DNA extraction was carried out according to the manufac-
turer’s instructions (69506; Qiagen, Sollentuna, Sweden).
Extracted DNA was quantiﬁed at 260-nm wavelength by
use of a NanoDrop (ND-1000; Thermo Fisher Scientiﬁc,
Wilmington, Del).
Extracellular matrix (ECM) staining and quantiﬁ-
cation. Brieﬂy, to demonstrate collagen and the connec-
tive tissues, the formalin-ﬁxed vein tissue sections were
reﬁxed overnight at room temperature in Bouin ﬁxative,
followed by staining with the Masson trichrome staining kit
(No. 25088; Polysciences Inc, Warrington, Pa). The dyes
employed during the staining procedure stained the
collagen ﬁbers blue, the nuclei black, and the cytoplasm
and muscle ﬁbers red.
Acid- and pepsin-soluble collagen quantiﬁcation.
The acid- and pepsin-soluble collagen content in the ECM
was measured by a Sircol soluble collagen assay kit (S1000;
Biocolor, County Antrim, United Kingdom). To extract
acid- and pepsin-soluble collagen, the 25 mg of native and
decellularized tissue (n ¼ 5) was digested with 0.5 M acetic
acid containing 0.1 mg/mL pepsin (P7012; Sigma-Aldrich,
Seelze, Germany) for 48 hours at 4C. The soluble collagen
was incubatedwith 1mLof Sircol dye reagent for 30minutes
at room temperature. The collagen-dye complex was
precipitated by centrifugation at 10,000 g for 10 minutes,
and the supernatantwas removed. The pellets were dissolved
in 1 mL of alkali reagent, and the relative absorbance was
measured in a 96-well plate at 555 nmby amicroplate reader
(PowerWave XS; BioTek Instruments, Winooski, Vt).
Sulfated glycosaminoglycan (GAG) quantiﬁcation.
The sulfated GAG content in the ECM was measured with a
Blyscan sulfatedGAG assay kit (B1000; Biocolor). To extract
sulfated GAGs, 25mg of native and decellularized tissue (n¼
5) was digested with a 0.2 M sodium phosphate buffer (pH,
6.8) containing 250 mg/mL of papain (P3125; Sigma-
Aldrich), 5 mM cysteine hydrochloride (C3290000; Sigma-
Aldrich), and 10 mM EDTA (ED2SS; Sigma-Aldrich) for 4
to 6 hours (until the tissue was completely dissolved) at 65C.
The suspension was centrifuged at 10,000 g for 10 minutes.
The extracted sulfated GAGs (100 mL) were mixed with
1 mL of Blyscan dye and shaken for 30 minutes. The pre-
cipitate was collected by centrifugation for 10 minutes and
then dissolved in 0.5 mL of dissociation reagent. The
absorbance was measured in a 96-well plate at 656 nm by a
microplate reader.
Soluble elastin quantiﬁcation. The soluble elastin
content in the ECM was measured by a Fastin elastin assaykit (F2000; Biocolor). To extract soluble elastin, 20 mg of
native and decellularized tissue (n ¼ 5) was hydrolyzed
with 0.25 M oxalic acid at 100C for 4 to 5 hours (until
the tissue was completely dissolved). The insoluble residues
were separated by centrifugation. The supernatant was
collected, and the sediment underwent an additional
extraction under the same conditions. The extracted solu-
ble elastin was mixed with 1 mL of Fastin dye and shaken
for 90 minutes. The precipitate was collected by centrifuga-
tion for 10 minutes and then dissolved in 250 mL of disso-
ciation reagent. The absorbance was measured in a 96-well
plate at 513 nm by a microplate reader.
Characterization of recellularized veins. To visualize
the presence of endothelial cells, antibodies to CD31
(1:100, ab9498; Abcam, Cambridge, UK) and von Wille-
brand factor (1:100, SC73268; Santa Cruz Biotechnology,
Heidelberg, Germany) were selected and stained by
immunohistochemistry and immunoﬂuorescence; smooth
muscle actin (1:50, ab7817; Abcam) was stained by immu-
nohistochemistry to visualize smooth muscle cells.
Biomechanical analysis. All biomechanical analyses
were performed at the SP Technical Research Institute,
Borås, Sweden. After the veins were cut open with surgical
scissors, the mechanical properties of the vein valve were
evaluated by tearing the valve in the horizontal direction
with the help of a 4-0 nonabsorbable monoﬁlament suture
made of polypropylene attached to the grips of an Instron
5566 (Instron, Norwood, Mass). A preload of 0.1 N with a
test speed of 20 mm/min was used. The accuracy of the
tensile tester is 0.5% in force and 0.5% in elongation, based
on calibrations performed regularly according to ISO
7500-1:2004 and ISO 9513:1999. Force at ﬁrst peak was
measured, and median force was calculated for each
sample.
Sterility control test. Sterility during recellularization
was evaluated by collecting 1 mL of perfused endothelial
and smooth muscle media collected after every 2 days dur-
ing culture and tested for microbial contaminants. About
500 mL of collected media was added to ﬂuid thioglycollate
broth, plated on tryptone soya agar plates, and incubated at
37C for 14 days. The medium exposed to outside air was
used as the positive control, and only the medium was used
as the negative control. The growth of fungi and aerobic
and anaerobic bacteria was visualized and also measured
in a spectrophotometer for absorbance at 600 nm. Differ-
ences in absorbance were noted.
Statistics. Results are presented as median and range.
The error bars represent the standard error mean for orig-
inal value. Mann-Whitney U tests were performed to
compare the effects of decellularization and recellulariza-
tion on the ECM and valves. P # .05 was considered to be
a signiﬁcant difference.
